Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization.
Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization.
复制标题
肝细胞癌肝移植：术前化疗栓塞的结果。
DOI：
10.1002/lt.500010409
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
J. Lake
中科院分区：
文献类型：
--
作者：
A. Venook;Linda D. Ferrell;J. Roberts;J. Emond;John W. Frye;Ernest J. Ring;N. Ascher;J. Lake
在加州大学旧金山分校弗朗西斯科，17名符合以下标准的患者-由于位置或肝脏储备不足而不可切除的肝肿瘤，无转移，HBsAg阴性，肿瘤直径不大于5 cm，并且不超过3个肿瘤--前瞻性地参加了一项采用术前化疗栓塞的方案，以评估原位肝移植（奥尔特）可以治愈大多数高度选择的肝细胞癌（HCC）患者。13例患者有活检证实的HCC，2例有纤维板层变异，2例有HCC的放射学发现，但没有活检证实。14例有基础肝病。所有动脉造影明显病变均使用明胶海绵粉、多柔比星、丝裂霉素-c和顺铂混合物进行化学栓塞。8例肝储备差的患者在供体器官可用时接受了化疗栓塞，而9例患者接受了化疗栓塞，然后被列入等待名单。化疗栓塞的唯一并发症是1例患者的胆囊坏疽。13例患者接受了肝移植（2例患者既往没有组织学证实为癌症，在奥尔特时没有可识别的肿瘤）; 3例患者在入组和供体器官可用性之间发生转移，随后死亡; 1例患者接受了三段切除术。11例经活检证实的HCC患者中有10例接受了移植，中位时间为40个月，无复发癌; 1例患者在6个月时死于淋巴组织增生性疾病，尸检时未发现癌症。虽然化疗栓塞的作用还不确定，但这些数据表明，大多数精心挑选的HCC患者可以通过奥尔特获得长期生存。
At the University of California, San Francisco, 17 patients who met the following criteria-hepatic tumor unresectable because of location or inadequate liver reserve, no metastases, HBsAg negative, no tumor larger than 5 cm in diameter, and no more than three tumors--were enrolled prospectively in a protocol employing preoperative chemoembolization to assess whether orthotopic liver transplantation (OLT) could cure a majority of highly selected patients with hepatocellular carcinoma (HCC). Thirteen patients had biopsy-proven HCC, 2 had the fibrolamellar variant, and 2 had radiological findings of HCC but no biopsy confirmation. Fourteen had underlying liver disease. All arteriographically apparent lesions were chemoembolized using a mixture including Gelfoam powder, doxorubicin, mitomycin-c, and cisplatin. Eight patients with poor hepatic reserve were chemoembolized when a donor organ became available, whereas 9 patients were chemoembolized and then placed on the waiting list. The only complication of chemoembolization was a gangrenous gallbladder in 1 patient. Thirteen patients underwent liver transplantation (2 patients without prior histological confirmation of carcinoma had no identifiable tumor at OLT); 3 patients developed metastases between the time of enrollment and donor organ availability and subsequently died; and 1 patient underwent a trisegmentectomy. Ten of the 11 patients with biopsy-proven HCC who underwent transplantation remain free of recurrent cancer at a median of 40 months; 1 patient died at 6 months of lymphoproliferative disease with no cancer found at autopsy. Although the role of chemoembolization is uncertain, these data show that the majority of carefully selected patients with HCC may achieve long-term survival with OLT.
采用肝次全切除或移植治疗纤维板层肝癌。
DOI：
10.1002/hep.510260412
发表时间：
1997
期刊：
Hepatology (Baltimore, Md.)
影响因子：
--
作者：
Pinna,AD;Iwatsuki,S;Lee,RG;Todo,S;Madariaga,JR;Marsh,JW;Casavilla,A;Dvorchik,I;Fung,JJ;Starzl,TE
通讯作者：
Starzl,TE
晚期肝细胞癌肝移植和癌症化疗后生存期延长。
影响因子：
0.9
作者：
Carr,BI;Selby,R;Madariaga,J;Iwatsuki,S;Starzl,TE
通讯作者：
Starzl,TE
DOI：
10.1200/jco.1992.10.10.1624
发表时间：
1992-10
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
A. Yahanda;K. M. Alder;G. Fisher;N. Brophy;J. Halsey;R. Hardy;M. Gosland;B. Lum;B. Sikic
通讯作者：
A. Yahanda;K. M. Alder;G. Fisher;N. Brophy;J. Halsey;R. Hardy;M. Gosland;B. Lum;B. Sikic